Clinical Trials Arena on MSN1d
AstraZeneca’s AZD0780 cuts LDL-C by 50% in Phase IIb trialAstraZeneca's AZD0780 has demonstrated significant efficacy in a Phase IIb trial, showing a 50.7% reduction in LDL-C after 12 ...
Pharmaceutical Technology on MSN1d
FDA approves AstraZeneca’s Imfinzi combo for bladder cancerThe US Food and Drug Administration (FDA) has approved AstraZeneca's human monoclonal antibody Imfinzi (durvalumab) with ...
AstraZeneca said on Friday it will spend $2.5 billion on a research and development hub in Beijing, as the drugmaker ...
Tallying up a wide range of investments, AstraZeneca said it is pumping $2.5 billion into Beijing. The figure includes ...
HONG KONG, LONDON] Ever since AstraZeneca shocked investors in October with news its China chief was under investigation, the ...
BEIJING] AstraZeneca will invest US$2.5 billion in a new research centre in Beijing, in a major show of commitment to China ...
AstraZeneca said on Friday it will spend Ksh.323 billion on a research and development hub in Beijing, as the drugmaker ...
The centre in Beijing will be the company's second R&D site in China - a centre in Shanghai opened in 2024 - to match two such centres each that AstraZeneca has in the U.S. and Europe ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback